Metabolic · 8 min read · Published September 8, 2026

Tesofensine Is Not a Peptide: What It Is, the Trials, and the Heart-Rate Issue

Tesofensine is a small-molecule triple monoamine reuptake inhibitor, not a peptide. The 2008 Lancet Phase 2 (203 patients, 24 weeks, about 10 percent weight loss at the top dose), the Mexican Phase 3 and stalled COFEPRIS application, the heart-rate signal that led to a beta-blocker combination, how it compares with phentermine, and why it ends up in peptide storefronts.

Is tesofensine a peptide?

No. Tesofensine is a synthetic small molecule of about 382 daltons that inhibits the presynaptic reuptake of noradrenaline, dopamine and serotonin. It is taken orally. It is not approved anywhere: the FDA and EMA have never received an application, and Mexico's COFEPRIS withheld approval in November 2024, with a resubmission filed in February 2025 still pending as of September 2026.

Tesofensine sits in peptide storefronts next to semaglutide and BPC-157 and gets called a 'peptide for weight loss' by people who have not checked. It is a centrally acting drug in the same broad family as sibutramine and bupropion: a triple monoamine reuptake inhibitor that raises three neurotransmitters in the synapse, which reduces appetite. Nothing about it is a chain of amino acids. Its status is investigational: Phase 3 completed in one country, approved in none.

Where did tesofensine come from?

From failed neurology trials. NeuroSearch tested it in Parkinson's and Alzheimer's disease; a 2008 pooled analysis of four trials (740 on tesofensine, 228 on placebo, 14 weeks, no diet) found dose-dependent weight loss up to 2.8 percent overall and 3.7 percent in obese patients, with heart rate up 2.1 to 6.8 beats per minute. The side effect became the product.

The 2008 Obesity meta-analysis is the cleanest look at tesofensine in people not trying to lose weight. Across the four neurology trials, weight change at 14 weeks was plus 0.5 percent on placebo and minus 0.5, 0.9, 1.8 and 2.8 percent at 0.125, 0.25, 0.5 and 1.0 mg, and 'no effect on blood pressure was observed' while heart rate rose significantly from the 0.25 mg dose (PubMed 18356831). Evidence tier: human RCT, pooled, secondary endpoint. The authors concluded that tesofensine was 'now being developed for obesity management'.

What did the Lancet Phase 2 trial show?

In TIPO-1 (Lancet, 2008), 203 obese adults were randomized to tesofensine 0.25, 0.5 or 1.0 mg or placebo daily for 24 weeks with an energy-restricted diet. Weight loss was 4.5, 9.2 and 10.6 percent versus 2.0 percent on placebo; 79 percent completed. Heart rate rose 7.4 beats per minute at 0.5 mg. Common adverse events: dry mouth, nausea, constipation, insomnia.

This is the trial the 'about 10 percent' figure comes from, and the numbers are real (PubMed 18950853). Evidence tier: human RCT. The authors wrote that 0.5 mg 'might have the potential to produce a weight loss twice that of currently approved drugs', a claim that predates GLP-1 drugs (see our GLP-1 field guide). First, blood pressure did not rise significantly at 0.25 and 0.5 mg, but the abstract is silent on the 1.0 mg arm, and later trials used only 0.25 and 0.5 mg. Second, in 2011 the Danish Health and Medicines Authority inspected the trial and found irregularities at two of the five sites, including consent taken by non-medical staff and incomplete adverse-event recording; The Lancet issued an Expression of Concern in April 2013. The inspection confirmed the endpoints and serious adverse events against source data, but found the published side-effect profile 'is not in accordance with the actual course of the trial' (Retraction Watch, 2013).

What happened in the Phase 3 and in Mexico?

Saniona's partner Medix ran the Viking Phase 3 in Mexico: 372 patients, 24 weeks, 0.25 or 0.5 mg daily versus placebo, about 10 percent loss, half losing over 10 percent (December 2018 press release). COFEPRIS gave a favorable technical opinion in 2023 but withheld approval on November 6, 2024; Medix resubmitted on February 20, 2025. No decision has been announced.

The Viking results exist only as a press release: both doses beat placebo (p below 0.001), waist circumference, visceral fat and triglycerides improved, and the release notes a 'low but statistically significant increase in heart rate' with no significant blood-pressure effect (Saniona press release, December 17, 2018). Evidence tier: human RCT, not published in a journal as far as we can find. The regulatory path since has been slow: a favorable but non-binding technical committee opinion in February 2023; a November 6, 2024 announcement that COFEPRIS had not approved the application, with Saniona citing a safety database of about 1,600 patients (Saniona, November 6, 2024); and a February 20, 2025 resubmission of the complete, roughly 20,000-page dossier (Saniona, February 20, 2025). We searched for a subsequent decision and found none as of September 8, 2026. Claims that tesofensine is 'approved in Mexico' are, on the public record, wrong.

Why is heart rate the problem?

Because a noradrenaline reuptake inhibitor stimulates sympathetic activity. Heart rate rose 7.4 beats per minute at 0.5 mg in TIPO-1 and dose-dependently in the neurology analysis. Saniona's answer was Tesomet, 0.5 mg tesofensine plus 50 mg metoprolol: in a 24-week trial of 21 adults with hypothalamic obesity it gave 6.3 percent more weight loss than placebo with no heart-rate difference.

The heart-rate signal is consistent across every tesofensine dataset, and the class history is poor: sibutramine, another noradrenaline and serotonin reuptake inhibitor, was withdrawn in 2010 after the SCOUT outcomes trial in patients with pre-existing cardiovascular risk found a 16 percent higher rate of major cardiovascular events (hazard ratio 1.16) (New England Journal of Medicine, 2010). The Tesomet program is the developer's own acknowledgment of the issue. In the European Journal of Endocrinology trial, 21 adults with hypothalamic obesity were randomized to Tesomet or placebo for 24 weeks; 18 completed; adverse events included sleep disturbance (50 versus 13 percent), dry mouth (43 versus 0) and headache (36 versus 0); and 'no significant differences in heart rate or blood pressure were observed between groups' (PubMed 35294397). Evidence tier: human RCT, small. A gray-market capsule delivers the reuptake inhibitor without the beta-blocker, without monitoring, and without the 1,600-patient safety database a regulator is still not satisfied with.

How does tesofensine compare with phentermine?

Phentermine is an approved sympathomimetic that releases noradrenaline; tesofensine blocks reuptake of three monoamines. In a 28-week trial (Aronne 2013), phentermine 7.5 mg and 15 mg got 43.3 and 46.2 percent to 5 percent loss versus 15.5 percent on placebo. Tesofensine's 24-week Phase 2 losses (9.2 to 10.6 percent) were larger, from a single 203-patient trial. Both raise heart rate.

The numbers suggest a stronger phentermine; the evidence base says not proven. The Aronne trial randomized obese adults to placebo, phentermine alone, topiramate alone or the combination for 28 weeks with lifestyle counseling; the combination reached 8.5 to 9.2 percent loss versus 1.7 percent on placebo, and each monotherapy was significantly weaker (PubMed 24136928). Evidence tier: human RCT. Phentermine has decades of prescribing history and a label with cardiovascular cautions; tesofensine has one published Phase 2 with an Expression of Concern, a Phase 3 known only from a press release, and no approval. GLP-1 peptides produced substantially larger losses over longer trials; see the semaglutide profile.

Why do peptide vendors sell it?

Because the gray market is organized by legal category, not chemistry. Tesofensine is an unapproved compound that can be labeled 'for research use only', like BPC-157 or retatrutide, and it is an oral capsule with an appetite effect, an easy add-on to a GLP-1 storefront. The label is a marketing device; sold for human use, it is an unapproved drug.

There is also a practical reason it travels with peptides: it is not a controlled substance the way phentermine is, it is cheap to synthesize, and its roughly eight-day half-life means once-daily oral dosing with a slow onset that customers read as 'gentle'. A capsule from an unregulated seller has no verified identity, purity or dose; our guide to reading a peptide certificate of analysis explains why a vendor COA does not settle that, and the FDA status tracker explains why 'research use only' is not a legal category for a drug taken by a person. Tesofensine was not part of the July 2026 compounding votes and has no route to legal supply in the United States.

The bottom line

Tesofensine is a real drug with real Phase 2 efficacy, a persistent heart-rate signal its own developer built a combination product to neutralize, a Phase 3 that has never been published, a Lancet paper carrying an Expression of Concern, and an approval application that Mexico's regulator has had in some form since before 2023 without granting. It is not a peptide, it is not approved, and its presence in peptide catalogs says more about how those catalogs are assembled than about the molecule.